Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S V Rajkumar

Showing results (71-80 of 172) with videos related to

Pageof 18
Sort By:
Leukemia|April 27, 2007
ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cellsM P Kline, S V Rajkumar, M M Timm, et al.
Blood Cancer Journal|June 25, 2021
Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patientsA Visram, C Soof, S V Rajkumar, et al.
Cancer Genetics and Cytogenetics|August 25, 1999
Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myelomaS V Rajkumar, R Fonseca, G W Dewald, et al.
Leukemia|August 10, 2011
MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphomaV Ramakrishnan, S Ansell, J Haug, et al.
Leukemia|June 29, 2020
N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progressionAngela Dispenzieri, D R Larson, S V Rajkumar, et al.
International Journal of Radiation Oncology, Biology, Physics|December 30, 1998
Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade gliomaS V Rajkumar, J C Buckner, P J Schomberg, et al.
Oncogene|November 26, 2009
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugsV Ramakrishnan, M Timm, J L Haug, et al.
Mayo Clinic Proceedings|September 20, 2000
Thalidomide in the treatment of relapsed multiple myelomaS V Rajkumar, R Fonseca, A Dispenzieri, et al.
Blood Cancer Journal|July 30, 2016
Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimenS J Jacobus, S V Rajkumar, M Weiss, et al.
Leukemia|October 12, 2011
Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapyS Sinha, M Lacy, J Mikhael, et al.
Pageof 18

Showing results (71-80 of 172) with videos related to

Sort By:
Pageof 18
Leukemia|April 27, 2007
ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cellsM P Kline, S V Rajkumar, M M Timm, et al.
Blood Cancer Journal|June 25, 2021
Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patientsA Visram, C Soof, S V Rajkumar, et al.
Cancer Genetics and Cytogenetics|August 25, 1999
Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myelomaS V Rajkumar, R Fonseca, G W Dewald, et al.
Leukemia|August 10, 2011
MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphomaV Ramakrishnan, S Ansell, J Haug, et al.
Leukemia|June 29, 2020
N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progressionAngela Dispenzieri, D R Larson, S V Rajkumar, et al.
International Journal of Radiation Oncology, Biology, Physics|December 30, 1998
Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade gliomaS V Rajkumar, J C Buckner, P J Schomberg, et al.
Oncogene|November 26, 2009
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugsV Ramakrishnan, M Timm, J L Haug, et al.
Mayo Clinic Proceedings|September 20, 2000
Thalidomide in the treatment of relapsed multiple myelomaS V Rajkumar, R Fonseca, A Dispenzieri, et al.
Blood Cancer Journal|July 30, 2016
Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimenS J Jacobus, S V Rajkumar, M Weiss, et al.
Leukemia|October 12, 2011
Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapyS Sinha, M Lacy, J Mikhael, et al.
Pageof 18